PACs derived from CMPs and GMPs possess robust angiogenic activity in vivo. (A) Matrigel plugs admixed with BM-derived CMPs, GMPs, HSCs, or MEPs grown in either EGM-2 or IMDM were subcutaneously implanted in 10-week-old, male C57BL/6 mice (n = 4/group). Matrigel plugs were harvested 8 days later, and CD31 and isolectin staining was quantitated (right). CMPs and GMPs grown in EGM-2 possessed high angiogenic potential compared with HSCs and MEPs and progenitors grown in IMDM. *P < .01 versus IMDM. **P < .05 versus IMDM. For Matrigel plugs, Matrigel images were photographed with an Olympus, Model SZ61 camera (top). For CD31 staining (middle), images were analyzed with an Olympus, Fluoview, Model FV1000 camera at 10× magnification and FV10-ASW Version 02.01 software. For isolectin (bottom), images were analyzed using an AQUA/PM2000 Imaging Platform (HistoRx), and automated quantitative analysis was performed with Software Suite Version 2.2 (HistoRx). (B) C57BL/6 mice underwent femoral artery ligation, and PACs dervied from CMPs, GMPs, HSCs, or MEPs were immediately injected intramuscularly at the ligation site. Blood flow recovery as visualized by laser Doppler imaging (785-nm near-infrared laser Doppler Imager-2; Moor Instruments) demonstrated increased ratios (ratio of ischemic thigh/contralateral thigh) in mice injected with PACs from CMPs and GMPs at days 7 and 14. *P < .05 versus MEP.